Real-world HbA1c changes and prescription characteristics among type 2 diabetes mellitus patients initiating treatment with once weekly semaglutide for diabetes
Purpose The purpose of this study was to evaluate patient, prescriber, and dose characteristics and evaluate changes in glycated hemoglobin (HbA 1c ) for patients prescribed once weekly semaglutide for diabetes (OW sema T2D). Methods This study was a retrospective claims-based study using the Optum...
Gespeichert in:
| Veröffentlicht in: | Journal of diabetes and metabolic disorders 2023-11, Vol.23 (1), p.727-737 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 737 |
|---|---|
| container_issue | 1 |
| container_start_page | 727 |
| container_title | Journal of diabetes and metabolic disorders |
| container_volume | 23 |
| creator | Frazer, Monica Swift, Caroline Sargent, Andrew Leszko, Michael Buysman, Erin Gronroos, Noelle N. Alvarez, Sara Dunn, Tyler J. Noone, Josh Gamble, Cory L. |
| description | Purpose
The purpose of this study was to evaluate patient, prescriber, and dose characteristics and evaluate changes in glycated hemoglobin (HbA
1c
) for patients prescribed once weekly semaglutide for diabetes (OW sema T2D).
Methods
This study was a retrospective claims-based study using the Optum Research Database. The sample included adult patients who had at least one claim for OW sema T2D between Jan 1, 2018, and Dec 31, 2019, were continuously enrolled in the health plan and had a diagnosis of type 2 diabetes (T2DM) during the pre-index or post-index periods. Demographic and clinical characteristics of patients using OW sema T2D were collected, as were the dose and prescriber specialty and the change between pre-index and post-index HbA
1c
measures was calculated. Results were stratified by the latest pre-index HbA
1c
measurement (HbA
1c
greater than or equal to 9.0%, uncontrolled vs. HbA
1c
less than 9%, controlled). Statistical comparisons between HbA
1c
groups were conducted.
Results
Most patients, 76.3%, were prescribed a 0.25/0.50 mg dose of OW sema T2D. Patients had an overall decrease in HbA
1c
of 0.8% and patients with uncontrolled diabetes had a greater reduction in mean HbA
1c
compared to those with controlled diabetes (-2.1% vs. -0.3%, p |
| doi_str_mv | 10.1007/s40200-023-01341-y |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11196477</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A774385499</galeid><sourcerecordid>A774385499</sourcerecordid><originalsourceid>FETCH-LOGICAL-c473t-a391edfed6f8324a57fb0b70fabcc1f095416cca36edf0ccad895f0c619833a3</originalsourceid><addsrcrecordid>eNp9kl9r1jAUxosoOOa-gFcBQbzpljRt017Jy1A3GAiy-5Cmp21mm9Qk9aXfZh_VUzvGXhCTi5wkv-chf54kec_oJaNUXIWcZpSmNOMpZTxn6foqOcuygqVlUbHXL-q3yUUIDxSbEFXFyrPk8QeoMT06P7bkpjkwTfSgbA-BKNuS2UPQ3szROLtteKUjeBOi0QhMzvYkrjOQjLRGNRBRNsE4mrgEMqtowMZAjDXR4GSDPag44So5mjgQZzWQI8DPcSUBJtWPSzQtkM75Z8N3yZtOjQEunsbz5P7rl_vrm_Tu-7fb68NdqnPBY6p4zaDtoC27ime5KkTX0EbQTjVas47WRc5KrRUvkaJYtFVdYFGyuuJc8fPk8247L80ErcYzejXK2ZtJ-VU6ZeTpjjWD7N1vyRiry1wIdPj05ODdrwVClJMJGl9DWXBLkJyKrGJ5TjmiH3a0VyNIYzuHlnrD5UGInFdFXtdIXf6Dwt7CZLSz0BlcPxF8fCEY8GPjENz2ps6GUzDbQe1dCB6653syKrdIyT1SEiMl_0ZKrijiuyggjAnx8sEt3uKf_E_1B7Ue02o</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3072814403</pqid></control><display><type>article</type><title>Real-world HbA1c changes and prescription characteristics among type 2 diabetes mellitus patients initiating treatment with once weekly semaglutide for diabetes</title><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Frazer, Monica ; Swift, Caroline ; Sargent, Andrew ; Leszko, Michael ; Buysman, Erin ; Gronroos, Noelle N. ; Alvarez, Sara ; Dunn, Tyler J. ; Noone, Josh ; Gamble, Cory L.</creator><creatorcontrib>Frazer, Monica ; Swift, Caroline ; Sargent, Andrew ; Leszko, Michael ; Buysman, Erin ; Gronroos, Noelle N. ; Alvarez, Sara ; Dunn, Tyler J. ; Noone, Josh ; Gamble, Cory L.</creatorcontrib><description>Purpose
The purpose of this study was to evaluate patient, prescriber, and dose characteristics and evaluate changes in glycated hemoglobin (HbA
1c
) for patients prescribed once weekly semaglutide for diabetes (OW sema T2D).
Methods
This study was a retrospective claims-based study using the Optum Research Database. The sample included adult patients who had at least one claim for OW sema T2D between Jan 1, 2018, and Dec 31, 2019, were continuously enrolled in the health plan and had a diagnosis of type 2 diabetes (T2DM) during the pre-index or post-index periods. Demographic and clinical characteristics of patients using OW sema T2D were collected, as were the dose and prescriber specialty and the change between pre-index and post-index HbA
1c
measures was calculated. Results were stratified by the latest pre-index HbA
1c
measurement (HbA
1c
greater than or equal to 9.0%, uncontrolled vs. HbA
1c
less than 9%, controlled). Statistical comparisons between HbA
1c
groups were conducted.
Results
Most patients, 76.3%, were prescribed a 0.25/0.50 mg dose of OW sema T2D. Patients had an overall decrease in HbA
1c
of 0.8% and patients with uncontrolled diabetes had a greater reduction in mean HbA
1c
compared to those with controlled diabetes (-2.1% vs. -0.3%, p < 0.001). Most patients had their index dose of OW sema T2D prescribed by endocrinologists (27.6%) primary care providers (24.6%) and internal medicine providers (21.6%).
Conclusions
OW sema T2D is an effective real-world T2DM treatment. Future research should further investigate real-world use patterns of this medication.</description><identifier>ISSN: 2251-6581</identifier><identifier>EISSN: 2251-6581</identifier><identifier>DOI: 10.1007/s40200-023-01341-y</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Analysis ; Diabetes ; Diabetes therapy ; Drug therapy ; Endocrinology ; Glycosylated hemoglobin ; Medical research ; Medicine ; Medicine & Public Health ; Medicine, Experimental ; Metabolic Diseases ; Online databases ; Research Article ; Type 2 diabetes</subject><ispartof>Journal of diabetes and metabolic disorders, 2023-11, Vol.23 (1), p.727-737</ispartof><rights>The Author(s) 2023</rights><rights>COPYRIGHT 2023 BioMed Central Ltd.</rights><rights>The Author(s) 2023.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c473t-a391edfed6f8324a57fb0b70fabcc1f095416cca36edf0ccad895f0c619833a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11196477/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11196477/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,41464,42533,51294,53766,53768</link.rule.ids></links><search><creatorcontrib>Frazer, Monica</creatorcontrib><creatorcontrib>Swift, Caroline</creatorcontrib><creatorcontrib>Sargent, Andrew</creatorcontrib><creatorcontrib>Leszko, Michael</creatorcontrib><creatorcontrib>Buysman, Erin</creatorcontrib><creatorcontrib>Gronroos, Noelle N.</creatorcontrib><creatorcontrib>Alvarez, Sara</creatorcontrib><creatorcontrib>Dunn, Tyler J.</creatorcontrib><creatorcontrib>Noone, Josh</creatorcontrib><creatorcontrib>Gamble, Cory L.</creatorcontrib><title>Real-world HbA1c changes and prescription characteristics among type 2 diabetes mellitus patients initiating treatment with once weekly semaglutide for diabetes</title><title>Journal of diabetes and metabolic disorders</title><addtitle>J Diabetes Metab Disord</addtitle><description>Purpose
The purpose of this study was to evaluate patient, prescriber, and dose characteristics and evaluate changes in glycated hemoglobin (HbA
1c
) for patients prescribed once weekly semaglutide for diabetes (OW sema T2D).
Methods
This study was a retrospective claims-based study using the Optum Research Database. The sample included adult patients who had at least one claim for OW sema T2D between Jan 1, 2018, and Dec 31, 2019, were continuously enrolled in the health plan and had a diagnosis of type 2 diabetes (T2DM) during the pre-index or post-index periods. Demographic and clinical characteristics of patients using OW sema T2D were collected, as were the dose and prescriber specialty and the change between pre-index and post-index HbA
1c
measures was calculated. Results were stratified by the latest pre-index HbA
1c
measurement (HbA
1c
greater than or equal to 9.0%, uncontrolled vs. HbA
1c
less than 9%, controlled). Statistical comparisons between HbA
1c
groups were conducted.
Results
Most patients, 76.3%, were prescribed a 0.25/0.50 mg dose of OW sema T2D. Patients had an overall decrease in HbA
1c
of 0.8% and patients with uncontrolled diabetes had a greater reduction in mean HbA
1c
compared to those with controlled diabetes (-2.1% vs. -0.3%, p < 0.001). Most patients had their index dose of OW sema T2D prescribed by endocrinologists (27.6%) primary care providers (24.6%) and internal medicine providers (21.6%).
Conclusions
OW sema T2D is an effective real-world T2DM treatment. Future research should further investigate real-world use patterns of this medication.</description><subject>Analysis</subject><subject>Diabetes</subject><subject>Diabetes therapy</subject><subject>Drug therapy</subject><subject>Endocrinology</subject><subject>Glycosylated hemoglobin</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Medicine, Experimental</subject><subject>Metabolic Diseases</subject><subject>Online databases</subject><subject>Research Article</subject><subject>Type 2 diabetes</subject><issn>2251-6581</issn><issn>2251-6581</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><recordid>eNp9kl9r1jAUxosoOOa-gFcBQbzpljRt017Jy1A3GAiy-5Cmp21mm9Qk9aXfZh_VUzvGXhCTi5wkv-chf54kec_oJaNUXIWcZpSmNOMpZTxn6foqOcuygqVlUbHXL-q3yUUIDxSbEFXFyrPk8QeoMT06P7bkpjkwTfSgbA-BKNuS2UPQ3szROLtteKUjeBOi0QhMzvYkrjOQjLRGNRBRNsE4mrgEMqtowMZAjDXR4GSDPag44So5mjgQZzWQI8DPcSUBJtWPSzQtkM75Z8N3yZtOjQEunsbz5P7rl_vrm_Tu-7fb68NdqnPBY6p4zaDtoC27ime5KkTX0EbQTjVas47WRc5KrRUvkaJYtFVdYFGyuuJc8fPk8247L80ErcYzejXK2ZtJ-VU6ZeTpjjWD7N1vyRiry1wIdPj05ODdrwVClJMJGl9DWXBLkJyKrGJ5TjmiH3a0VyNIYzuHlnrD5UGInFdFXtdIXf6Dwt7CZLSz0BlcPxF8fCEY8GPjENz2ps6GUzDbQe1dCB6653syKrdIyT1SEiMl_0ZKrijiuyggjAnx8sEt3uKf_E_1B7Ue02o</recordid><startdate>20231127</startdate><enddate>20231127</enddate><creator>Frazer, Monica</creator><creator>Swift, Caroline</creator><creator>Sargent, Andrew</creator><creator>Leszko, Michael</creator><creator>Buysman, Erin</creator><creator>Gronroos, Noelle N.</creator><creator>Alvarez, Sara</creator><creator>Dunn, Tyler J.</creator><creator>Noone, Josh</creator><creator>Gamble, Cory L.</creator><general>Springer International Publishing</general><general>BioMed Central Ltd</general><scope>C6C</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20231127</creationdate><title>Real-world HbA1c changes and prescription characteristics among type 2 diabetes mellitus patients initiating treatment with once weekly semaglutide for diabetes</title><author>Frazer, Monica ; Swift, Caroline ; Sargent, Andrew ; Leszko, Michael ; Buysman, Erin ; Gronroos, Noelle N. ; Alvarez, Sara ; Dunn, Tyler J. ; Noone, Josh ; Gamble, Cory L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c473t-a391edfed6f8324a57fb0b70fabcc1f095416cca36edf0ccad895f0c619833a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Analysis</topic><topic>Diabetes</topic><topic>Diabetes therapy</topic><topic>Drug therapy</topic><topic>Endocrinology</topic><topic>Glycosylated hemoglobin</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Medicine, Experimental</topic><topic>Metabolic Diseases</topic><topic>Online databases</topic><topic>Research Article</topic><topic>Type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Frazer, Monica</creatorcontrib><creatorcontrib>Swift, Caroline</creatorcontrib><creatorcontrib>Sargent, Andrew</creatorcontrib><creatorcontrib>Leszko, Michael</creatorcontrib><creatorcontrib>Buysman, Erin</creatorcontrib><creatorcontrib>Gronroos, Noelle N.</creatorcontrib><creatorcontrib>Alvarez, Sara</creatorcontrib><creatorcontrib>Dunn, Tyler J.</creatorcontrib><creatorcontrib>Noone, Josh</creatorcontrib><creatorcontrib>Gamble, Cory L.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of diabetes and metabolic disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Frazer, Monica</au><au>Swift, Caroline</au><au>Sargent, Andrew</au><au>Leszko, Michael</au><au>Buysman, Erin</au><au>Gronroos, Noelle N.</au><au>Alvarez, Sara</au><au>Dunn, Tyler J.</au><au>Noone, Josh</au><au>Gamble, Cory L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Real-world HbA1c changes and prescription characteristics among type 2 diabetes mellitus patients initiating treatment with once weekly semaglutide for diabetes</atitle><jtitle>Journal of diabetes and metabolic disorders</jtitle><stitle>J Diabetes Metab Disord</stitle><date>2023-11-27</date><risdate>2023</risdate><volume>23</volume><issue>1</issue><spage>727</spage><epage>737</epage><pages>727-737</pages><issn>2251-6581</issn><eissn>2251-6581</eissn><abstract>Purpose
The purpose of this study was to evaluate patient, prescriber, and dose characteristics and evaluate changes in glycated hemoglobin (HbA
1c
) for patients prescribed once weekly semaglutide for diabetes (OW sema T2D).
Methods
This study was a retrospective claims-based study using the Optum Research Database. The sample included adult patients who had at least one claim for OW sema T2D between Jan 1, 2018, and Dec 31, 2019, were continuously enrolled in the health plan and had a diagnosis of type 2 diabetes (T2DM) during the pre-index or post-index periods. Demographic and clinical characteristics of patients using OW sema T2D were collected, as were the dose and prescriber specialty and the change between pre-index and post-index HbA
1c
measures was calculated. Results were stratified by the latest pre-index HbA
1c
measurement (HbA
1c
greater than or equal to 9.0%, uncontrolled vs. HbA
1c
less than 9%, controlled). Statistical comparisons between HbA
1c
groups were conducted.
Results
Most patients, 76.3%, were prescribed a 0.25/0.50 mg dose of OW sema T2D. Patients had an overall decrease in HbA
1c
of 0.8% and patients with uncontrolled diabetes had a greater reduction in mean HbA
1c
compared to those with controlled diabetes (-2.1% vs. -0.3%, p < 0.001). Most patients had their index dose of OW sema T2D prescribed by endocrinologists (27.6%) primary care providers (24.6%) and internal medicine providers (21.6%).
Conclusions
OW sema T2D is an effective real-world T2DM treatment. Future research should further investigate real-world use patterns of this medication.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><doi>10.1007/s40200-023-01341-y</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2251-6581 |
| ispartof | Journal of diabetes and metabolic disorders, 2023-11, Vol.23 (1), p.727-737 |
| issn | 2251-6581 2251-6581 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11196477 |
| source | PubMed Central; SpringerLink Journals - AutoHoldings |
| subjects | Analysis Diabetes Diabetes therapy Drug therapy Endocrinology Glycosylated hemoglobin Medical research Medicine Medicine & Public Health Medicine, Experimental Metabolic Diseases Online databases Research Article Type 2 diabetes |
| title | Real-world HbA1c changes and prescription characteristics among type 2 diabetes mellitus patients initiating treatment with once weekly semaglutide for diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T23%3A27%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Real-world%20HbA1c%20changes%20and%20prescription%20characteristics%20among%20type%202%20diabetes%20mellitus%20patients%20initiating%20treatment%20with%20once%20weekly%20semaglutide%20for%20diabetes&rft.jtitle=Journal%20of%20diabetes%20and%20metabolic%20disorders&rft.au=Frazer,%20Monica&rft.date=2023-11-27&rft.volume=23&rft.issue=1&rft.spage=727&rft.epage=737&rft.pages=727-737&rft.issn=2251-6581&rft.eissn=2251-6581&rft_id=info:doi/10.1007/s40200-023-01341-y&rft_dat=%3Cgale_pubme%3EA774385499%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3072814403&rft_id=info:pmid/&rft_galeid=A774385499&rfr_iscdi=true |